Clinical Trial Results:
Un Ensayo de Fase IIb, Aleatorizado, Doble Ciego, Controlado con Placebo y Comparador Activo, de Determinación del Rango de Dosis para Evaluar los Efectos de MK-5442 en la Densidad Mineral Ósea (DMO) en el Tratamiento de la Osteoporosis en Mujeres Posmenopáusicas Tratadas Anteriormente con un Bifosfonato Oral
"A Phase IIb, Randomized, Double-Blind, Placebo- and Active-Controlled, Dose-Range-Finding Study to Evaluate the Effects of MK-5442 on Bone Mineral Density (BMD) in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated with an Oral Bisphosphonate"
Summary
|
|
EudraCT number |
2009-014729-18 |
Trial protocol |
ES GB CZ DK PL FR |
Global completion date |
16 Jun 2011
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
29 Jun 2016
|
First version publication date |
29 Jun 2016
|
Other versions |
|
Summary report(s) |
clinicaltrials.gov record including results |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.